Peroxisome proliferator-activated receptor ligands in atherosclerosis

By Viles-Gonzalez Juan F   Choi Brian G   Fuster Valentin   Badimon Juan J  

Expert Opinion on Investigational Drugs, Vol. 13, Iss. 11, 2004-11 ,pp. : 1393-1403

Informa Healthcare

Access to resources Recommend Favorite

Neuroprotective Properties of Peroxisome Proliferator-Activated Receptor Alpha (PPAR) and its Lipid Ligands

By  

Current Medicinal Chemistry, Vol. 21, Iss. 24, 2014-08 ,pp. : 2803-2821

Bentham Science Publishers

Access to resources Recommend Favorite

The Need for Physiologically Relevant Peroxisome Proliferator-Activated Receptor-gamma (PPAR-γ) Ligands

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 13, Iss. 2, 2013-06 ,pp. : 175-183

Bentham Science Publishers

Access to resources Recommend Favorite

Design, Synthesis, and Structure-Activity Relationship Study of Peroxisome Proliferator-Activated Receptor (PPAR) &dgr;-Selective Ligands

By  

Current Medicinal Chemistry, Vol. 14, Iss. 22, 2007-09 ,pp. : 2335-2343

Bentham Science Publishers

Access to resources Recommend Favorite

Synthetic ligands for peroxisome proliferator-activated receptor-α, review of the patent literature 2000 – 2003

By Miyachi Hiroyuki  

Expert Opinion on Therapeutic Patents, Vol. 14, Iss. 5, 2004-05 ,pp. : 607-618

Informa Healthcare

Access to resources Recommend Favorite